Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Summary of studies using Nrf2 inhibitor

Nrf2 inhibitor Concentration Cell line Therapeutic agents used with Nrf2 inhibitor
 Trigonelline57 0.1-0.5 μM Panc1, Colo357 Etoposide
Vitamin C
 Ascorbic acid61 0.125 mM KCL22 Imatinib
 Brusatol60 40 nM A549 CisplatinCarboplatin, 5-fluorouracil, Etoposide, Paclitaxel
 Chrysin58 10-20 μM BEL-7402 Doxorubicin
 Apigenin59 10-20 μM BEL-7402 Doxorubicin
 Luteolin62 1-20 μM MCF7, Caco2, A549 Actinomycin D, Oxaliplatin, Bleomycin, Doxorubicin

Nrf2, nuclear factor E2-related factor 2.

Journal of Cancer Prevention 2014;19:111~117
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd